Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Maruho Grabs Global Rights to RaQualia’s Sodium Channel Blocker
December 26, 2017
- MHLW to Use Its Classification Table to Pick PMP-Eligible Similar Drugs; How Will 3 Year 3rd Product Rule Affect I/O and Other Meds?
December 26, 2017
- 86 Apply for Voluntary Redundancy for Manufacturing Jobs: Sumitomo Dainippon
December 26, 2017
- TB Vaccine Joint Venture to Be Dissolved: Sumitomo Dainippon, Japan BCG, INCJ
December 26, 2017
- Kyowa Kirin Taps Miyamoto as President and COO
December 25, 2017
- Opdivo Filed for Dosage Change, Label Expansion in Japan
December 25, 2017
- Eisai/Biogen’s Alzheimer’s Candidate BAN2401 Disappoints in PII
December 25, 2017
- Mylan EPD to Take Over EpiPen from Pfizer in Japan
December 22, 2017
- Mitsubishi Tanabe Seeks to Call Off Cell Therapy Deal with South Korea’s KLS
December 21, 2017
- Pfizer, Maruishi File Precedex for Pediatric Use
December 21, 2017
- Otsuka Partners with US Biotech X-Chem on Oncology Drug Discovery
December 21, 2017
- GSK Japan Pres. Kikuchi to Quit after Only 9 Months in Office
December 20, 2017
- Fujifilm Grabs Stake in Genome Editing Startup, Makes Inroads into Gene Therapy Space
December 20, 2017
- JCR, Medipal to Form US Joint Venture Next Month
December 20, 2017
- Ono Cuts Computational Drug Discovery Deal with Schrödinger
December 20, 2017
- Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020
December 20, 2017
- Pfizer to Lift Selara Shipment Adjustment, Normalizing Supply of All Hurricane-Hit Products
December 20, 2017
- Mundipharma to Enter Japanese Anesthesia Market with Remimazolam Licensed from German Company
December 20, 2017
- Janssen, Taiho to Copromote Psoriasis Med Guselkumab
December 19, 2017
- Kyowa Kirin’s Burosumab Gains European Panel Backing for Conditional Approval
December 19, 2017
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…